<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03376672</url>
  </required_header>
  <id_info>
    <org_study_id>NMSG#23/15</org_study_id>
    <nct_id>NCT03376672</nct_id>
  </id_info>
  <brief_title>Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients</brief_title>
  <official_title>A Prospective Phase 2 Study to Assess the Minimal Residual Disease After Ixazomib Plus Lenalidomide Plus Dexamethasone (IRd) Treatment for Newly Diagnosed Transplant Eligible Myeloma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raija Silvennoinen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Myeloma Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of 3-drug all-oral combination, ixazomib
      plus lenalidomide plus dexamethasone (IRd) as induction treatment for autologous stem cell
      transplantation eligible patients followed by IRd consolidation and risk based maintenance
      treatment with IR or R alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Nordic Myeloma Study Group study is phase 2 study for newly diagnosed transplant
      eligible myeloma patients between 18 - 70 years of age. Patients will have four IRd cycles of
      28 day each as induction consisting of ixazomib 4 mg on days 1, 8 and 15 and lenalidomide 25
      mg on days 1-21 and dexamethasone 40 mg on days 1, 8, 15 and 22. After autologous stem cell
      mobilisation and transplantation patients will receive 2 consolidation cycles with the same
      combination as during induction. This is followed by risk based maintenance so that high-risk
      patients will have ixazomib plus lenalidomide maintenance and standard-low risk patients
      lenalidomide alone. The treatment will continue until progression or excess toxicity. The
      primary endpoint is minimal residual disease &lt; 0.01% assessed by 8-color flow cytometry
      (EuroFlow) and secondary endpoint is achievement of minimal residual negativity status
      assessed by 8-color flow cytometry. Other secondary endpoints are safety, improvement of
      response during maintenance treatment, progression free survival, time to next treatment,
      quality of life and overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow cytometric assessment &lt; 0.01%</measure>
    <time_frame>48 months</time_frame>
    <description>Minimal residual disease by multiparameter flow cytometry (MFC) &lt; 0.01%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flow cytometry negativity</measure>
    <time_frame>48 months</time_frame>
    <description>Minimal residual disease negativity by MFC</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Survival time</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Time without progression of myeloma</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Ixazomib,lenalidomide,dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib capsules 4Mg Oral capsule on days 1, 8 and 15 in 28d cycle, lenalidomide 25 milligram capsules on days 1-21 in 28d cycle, dexamethasone 40 milligram capsules on days 1, 8, 15, 22 in 28d cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk maintenance arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib capsules 4Mg Oral capsule on days 1, 8, 15, lenalidomide 10 milligram on days 1-21 in 28d cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard and low risk maintenance arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib</intervention_name>
    <description>All patients will have similar induction and consolidation treatment with the same regimen.</description>
    <arm_group_label>Ixazomib,lenalidomide,dexamethasone</arm_group_label>
    <arm_group_label>High risk maintenance arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>All patients will have similar induction and consolidation treatment with the same regimen.</description>
    <arm_group_label>Ixazomib,lenalidomide,dexamethasone</arm_group_label>
    <arm_group_label>High risk maintenance arm</arm_group_label>
    <arm_group_label>Standard and low risk maintenance arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>All patients will have similar induction and consolidation treatment with the same regimen.</description>
    <arm_group_label>Ixazomib,lenalidomide,dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed transplant eligible male or female multiple myeloma patients, 18-70
             years of age, who have not received prior treatment for multiple myeloma

          2. Symptomatic and measurable disease diagnosed by standard criteria (International
             Myeloma Working Group, CRAB criteria)

          3. Voluntary written informed consent must be given before performance of any study
             related procedure not part of standard medical care, with the understanding that
             consent may be withdrawn by the patient at any time without prejudice to future
             medical care.

          4. Female patients who:

               -  Are postmenopausal for at least 1 year before the screening visit, OR

               -  Are surgically sterile, OR

               -  If they are of childbearing potential, fertile, agree to practice 2 effective
                  methods of contraception, at the same time, and agree to ongoing pregnancy
                  testing and adhere to the guidelines of the lenalidomide pregnancy prevention
                  program from the time of signing the informed consent form through 90 days after
                  the last dose of study drug, OR

               -  Agree to practice true abstinence when this is in line with the preferred and
                  usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation,
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods
                  of contraception.)

        Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree to one
        of the following:

        • Agree to practice effective barrier contraception and adhere to the guidelines of the
        lenalidomide pregnancy prevention program during the entire study treatment period and
        through 90 days after the last dose of study drug, OR

          -  Agree to practice true abstinence when this is in line with the preferred and usual
             lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation,
             symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of
             contraception.

             4. Patients must have a diagnosis of a symptomatic multiple myeloma without any
             previous therapies except dexamethasone 160 mg dose, or comparable dose of other
             steroids, and local radiotherapy for symptom control 5. Eastern Cooperative Oncology
             Group (ECOG) performance status and/or other performance status 0, 1, or 2.

             6. Patients must meet the following clinical laboratory criteria:

          -  Absolute neutrophil count (ANC) ≥ 1,000/mm3 (≥ 1.0 x 109/L) and platelet count ≥
             75,000/mm3 (75 x 109/L). Platelet transfusions to help patients meet eligibility
             criteria are not allowed within 3 days before study enrollment.

          -  Total bilirubin ≤ 1.5 × the upper limit of the normal range (ULN).

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN.

          -  Calculated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault estimation of creatinine
             clearance (CRcl): CRcl (mL/min) = (140 - age) (weight [kg]) / 72 (serum creatinine
             [mg/dL]); for females, multiply by 0.85 (Cockcroft DW. 1976, Luke DR. 1990).

             7. Patient must be willing and able to adhere to the study protocol visit schedule and
             other protocol requirements.

             8. Negative pregnancy test at inclusion if applicable

        Exclusion Criteria:

          -  1. Female patients who are lactating or have a positive serum pregnancy test during
             the screening period.

             2. Major surgery within 14 days before enrollment. 3. Radiotherapy within 14 days
             before enrollment 4. Central nervous system involvement with multiple myeloma. 5.
             Infection requiring systemic antibiotic therapy or other serious infection within 14
             days before study enrollment.

             6. Inability, unwillingness or contraindication to use thrombosis prophylaxis or
             antithrombotic therapy or herpes zoster prophylaxis 7. Evidence of current
             uncontrolled cardiovascular conditions, including uncontrolled hypertension,
             uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable
             angina, or myocardial infarction within the past 6 months.

             8. Systemic treatment, within 14 days before the first dose of ixazomib, strong CYP3A
             inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital),
             or use of Ginkgo biloba or St. John's wort.

             9. Ongoing or active systemic infection, active hepatitis B or C virus infection, or
             known human immunodeficiency virus (HIV) positive.

             10. Any serious medical or psychiatric illness that could, in the investigator's
             opinion, potentially interfere with the completion of treatment according to this
             protocol.

             11. Known allergy to any of the study medications, their analogues, or excipients in
             the various formulations of any agent.

             12. Known GI disease or GI procedure that could interfere with the oral absorption or
             tolerance of ixazomib or lenalidomide including difficulty swallowing.

             13. Diagnosed or treated for another malignancy within 5 years before study enrollment
             or previously diagnosed with another malignancy and have any evidence of residual
             disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are
             not excluded if they have undergone complete resection.

             14. Patient has Grade 1 polyneuropathy with pain on clinical examination during the
             screening period.

             15. Participation in other clinical trials, including those with other investigational
             agents not included in this trial, within 30 days of the start of this trial and
             throughout the duration of this trial.

             16. Patients that have previously been treated for multiple myeloma or smoldering
             myeloma with ixazomib or any other therapy, or participated in a study with ixazomib
             whether treated with ixazomib or not.

             17. Primary plasma cell leukemia, POEMS syndrome, Waldenström disease, myelodysplastic
             syndrome or myeloproliferative disease

             18. Systemic AL amyloidosis/primary amyloidosis or myeloma associated amyloidosis.

             19. Allogeneic stem cell transplantation planned

             20. Participants receiving any other investigational agents or received within 60 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raija H Silvennoinen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raija H Silvennoinen, MD, PhD</last_name>
    <phone>+358 50 327 6348</phone>
    <email>raija.silvennoinen@helsinki.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hareth Nahi, MD, PhD</last_name>
    <email>hareth.nahi@karolinska.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Finland Central Hospital</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anu Sikiö, MD</last_name>
      <email>anu.sikio@ksshp.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kainuu Central Hospital</name>
      <address>
        <city>Kajaani</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymenlaakso Central Hospital</name>
      <address>
        <city>Kotka</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anu Räsänen, MD</last_name>
      <email>anu.rasanen@carea.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anu Partanen, MD</last_name>
      <email>anu.partanen@kuh.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Päijät-Häme Cebtral Hospital</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marjaana Säily, MD, PhD</last_name>
      <email>marjaana.saily@ppshp.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VIlnius University Hospital</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forde Central Hospital South</name>
      <address>
        <city>Forde</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trondheim University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borås University Hospital</name>
      <address>
        <city>Borås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulf-Henrik Mellqvist, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Göteborg University Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cecilie Blimark, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Halmstad Hospital Region Halland</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Conny Karlsson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Ahlberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunderby Hospital Region Norrbotten</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Birgitta Lauri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingborg Hospital Skane</name>
      <address>
        <city>Skane</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Per Axelsson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uddevalla Hospital</name>
      <address>
        <city>Uddevalla</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johanna Abelsson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristina Carlson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Varberg Hospital</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mikael Olsson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olle Linder, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Lithuania</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Raija Silvennoinen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

